HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jan. 15, 2019--
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it
has completed its $250 million share repurchase program. The company
bought back 2,493,378 of its ordinary shares in open market transactions
at an average price of $100.28 per share. The repurchase program was
announced by the company on November 23, 2016, and was completed on
January 11, 2019.
Taro Pharmaceutical Industries Ltd. is a multinational, science-based
pharmaceutical company, dedicated to meeting the needs of its customers
through the discovery, development, manufacturing and marketing of the
highest quality healthcare products. For further information on Taro
Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190115005928/en/
Source: Taro Pharmaceutical Industries Ltd.
Mariano A. Balaguer
AVP, Business Finance, Treasurer and Investor Relations